This phase I trial studies the side effects and best dose of AOH1996 in treating patients with solid tumors that do not respond to treatment (refractory). AOH1996 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
1. Documented informed consent by the participant
2. Willingness to permit study team to obtain and use archival tissue, if already existing
3. Age: ≥ 18 years
4. ECOG performance status ≤ 2
2. Other investigational products or chemotherapy. Exception: EGFR TKI in the NSCLC expansion cohort is allowed.
3. Warfarin
4. Current or planned use of agents contraindicated for use with strong CYP3A4 inducers
5. Strong inhibitors or inducers of CYP2C9
City of Hope Medical Center
Lead sponsor
National Cancer Institute (NCI)
Collaborator